The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view

Oscar D Sanchez, Kazuyuki Yahagi, Tobias Koppara, Renu Virmani, Michael Joner CVPath Institute, Inc., Gaithersburg, MD, USA Abstract: Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide. The pathogenesis of CAD relates to the presence of atherosclerotic plaques...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sanchez OD, Yahagi K, Koppara T, Virmani R, Joner M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/f3c7b85480ef4681842bafddcb06762f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f3c7b85480ef4681842bafddcb06762f
record_format	dspace
spelling	oai:doaj.org-article:f3c7b85480ef4681842bafddcb06762f2021-12-02T05:55:41ZThe everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view1179-1470https://doaj.org/article/f3c7b85480ef4681842bafddcb06762f2014-12-01T00:00:00Zhttp://www.dovepress.com/the-everolimus-eluting-xience-stent-in-small-vessel-disease-bench-clin-peer-reviewed-article-MDERhttps://doaj.org/toc/1179-1470 Oscar D Sanchez, Kazuyuki Yahagi, Tobias Koppara, Renu Virmani, Michael Joner CVPath Institute, Inc., Gaithersburg, MD, USA Abstract: Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide. The pathogenesis of CAD relates to the presence of atherosclerotic plaques in the coronary arteries, which are most frequently treated today by percutaneous coronary intervention. Small vessel disease treatment represents one-third of all percutaneous coronary interventions with higher rates of restenosis and major adverse cardiac events. Initially, drug-eluting stents (DES) were developed to reduce in-stent restenosis, improving clinical outcomes and reducing the need for target vessel revascularization. However, late and very late stent thrombosis emerged as a new problem compromising DES's long-term results. The cobalt–chromium everolimus-eluting stent (CoCr-EES) represents the results of an evolutionary process in DES technology aimed at improving the shortcomings of first-generation DES. Small vessel CAD has historically been an obstacle to long-term patency following implantation of DES. Antirestenotic efficacy has been shown to be of high relevance in small vessels. Therefore, stent selection may play an important role in determining outcomes in this subgroup of patients. This article will review the performance of CoCr-EES in the treatment of small vessel CAD from preclinical, clinical, and pathology perspectives, and it will highlight the most important findings in this regard. Keywords: small vessel, cobalt–chromiun everolimus-eluting stent, Xience V, pathologySanchez ODYahagi KKoppara TVirmani RJoner MDove Medical PressarticleMedical technologyR855-855.5ENMedical Devices: Evidence and Research, Vol 2015, Iss default, Pp 37-45 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medical technology R855-855.5
spellingShingle	Medical technology R855-855.5 Sanchez OD Yahagi K Koppara T Virmani R Joner M The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view
description	Oscar D Sanchez, Kazuyuki Yahagi, Tobias Koppara, Renu Virmani, Michael Joner CVPath Institute, Inc., Gaithersburg, MD, USA Abstract: Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide. The pathogenesis of CAD relates to the presence of atherosclerotic plaques in the coronary arteries, which are most frequently treated today by percutaneous coronary intervention. Small vessel disease treatment represents one-third of all percutaneous coronary interventions with higher rates of restenosis and major adverse cardiac events. Initially, drug-eluting stents (DES) were developed to reduce in-stent restenosis, improving clinical outcomes and reducing the need for target vessel revascularization. However, late and very late stent thrombosis emerged as a new problem compromising DES's long-term results. The cobalt–chromium everolimus-eluting stent (CoCr-EES) represents the results of an evolutionary process in DES technology aimed at improving the shortcomings of first-generation DES. Small vessel CAD has historically been an obstacle to long-term patency following implantation of DES. Antirestenotic efficacy has been shown to be of high relevance in small vessels. Therefore, stent selection may play an important role in determining outcomes in this subgroup of patients. This article will review the performance of CoCr-EES in the treatment of small vessel CAD from preclinical, clinical, and pathology perspectives, and it will highlight the most important findings in this regard. Keywords: small vessel, cobalt–chromiun everolimus-eluting stent, Xience V, pathology
format	article
author	Sanchez OD Yahagi K Koppara T Virmani R Joner M
author_facet	Sanchez OD Yahagi K Koppara T Virmani R Joner M
author_sort	Sanchez OD
title	The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view
title_short	The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view
title_full	The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view
title_fullStr	The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view
title_full_unstemmed	The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view
title_sort	everolimus-eluting xience stent in small vessel disease: bench, clinical, and pathology view
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/f3c7b85480ef4681842bafddcb06762f
work_keys_str_mv	AT sanchezod theeverolimuselutingxiencestentinsmallvesseldiseasebenchclinicalandpathologyview AT yahagik theeverolimuselutingxiencestentinsmallvesseldiseasebenchclinicalandpathologyview AT kopparat theeverolimuselutingxiencestentinsmallvesseldiseasebenchclinicalandpathologyview AT virmanir theeverolimuselutingxiencestentinsmallvesseldiseasebenchclinicalandpathologyview AT jonerm theeverolimuselutingxiencestentinsmallvesseldiseasebenchclinicalandpathologyview AT sanchezod everolimuselutingxiencestentinsmallvesseldiseasebenchclinicalandpathologyview AT yahagik everolimuselutingxiencestentinsmallvesseldiseasebenchclinicalandpathologyview AT kopparat everolimuselutingxiencestentinsmallvesseldiseasebenchclinicalandpathologyview AT virmanir everolimuselutingxiencestentinsmallvesseldiseasebenchclinicalandpathologyview AT jonerm everolimuselutingxiencestentinsmallvesseldiseasebenchclinicalandpathologyview
_version_	1718400209608769536

The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view

Ejemplares similares